Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
Honeywell (NASDAQ: HON) announced the anticipated 11‑member Board of Directors for the planned standalone Honeywell Aerospace, led by Independent Chair Craig Arnold and including CEO Jim Currier. The spin‑off is expected to be completed on June 29, 2026, with an Investor Day scheduled for June 3, 2026.
The board combines aerospace, defense, finance, and capital‑markets experience intended to support electrification, autonomy, and safety initiatives as the company launches as a public pure‑play aerospace and defense firm.
DaVita (NYSE: DVA) will host its first quarter 2026 earnings conference call on Tuesday, May 5, 2026 at 5:00 p.m. Eastern Time. The company will release results after market close the same day and will webcast the call on its investor relations site.
Investors can join via webcast or by dialing the provided domestic and international numbers; a website replay will be available after the live event.
DaVita (NYSE:DVA) highlighted progress in value-based kidney care on March 18, 2026, citing improved quality metrics, shared savings and scale in coordinated care.
Key points: a 9% Total Quality Score improvement, >$200 million in cumulative shared savings, and management of $5+ billion in medical costs under management, tied to better treatment starts and reduced catheter use.
Alebund Pharmaceuticals (NYSE:DVA) granted R1 Therapeutics exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China and received a substantial non-dilutive equity stake in R1.
The deal includes up to low triple‑digit millions in milestone payments, tiered royalties in the low double‑digit percent range, and a planned global Phase 2b MRCT starting later this year.
DaVita (NYSE: DVA) will participate in TD Cowen's 46th Annual Health Care Conference with CFO Joel Ackerman and VP of Investor Relations Nic Eliason in a fireside chat on March 2, 2026 at 11:50 am EST. A live webcast is available via TD Cowen with free registration.
As of Dec 31, 2025, DaVita served ~295,000 patients across 3,242 outpatient dialysis centers globally.
DaVita (NYSE: DVA) reported consolidated revenues of $3.620B for Q4 2025 and $13.643B for full-year 2025, adjusted diluted EPS of $3.40 (Q4) and $10.78 (2025), operating cash flow of $541M (Q4) and free cash flow of $1,024M (2025).
The company refinanced Term Loan A-1, issued 6.75% senior notes due 2033, repurchased 12.7M shares in 2025, and provided 2026 guidance for adjusted operating income and adjusted EPS.
Elara Caring announced a strategic investment from Ares and DaVita (DVA) to expand clinically advanced, in‑home care for complex and high‑acuity patients. The partners will co‑develop a kidney‑specific home care model and support Elara’s scale-up while Elara remains an independent company led by CEO Ananth Mohan.
The transaction is subject to customary closing conditions and regulatory approvals, with closing expected later in 2026; financial terms were not disclosed.
DaVita (NYSE: DVA) will hold its fourth quarter 2025 earnings conference call on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release fourth quarter results after market close the same day. The call will be webcast and accessible via the DaVita investor relations web page; a live dial‑in is available (U.S. 877-918-6630; international 517-308-9042) and callers should provide the password "Earnings".
Investors unable to listen live can access a replay on the company website; there will be no telephone replay.
Tolion Health AI (DVA) appointed Gregory J. Moore, MD, PhD, to its board on January 6, 2026, strengthening clinical, AI, regulatory, and global growth expertise.
Dr. Moore brings experience leading health and life-sciences teams at Microsoft and Google, board service at DaVita and Fortive, and academic and clinical credentials. Tolion highlighted its 2025 US launch of Tolion Brain Coach on the Apple App Store, recent fundraising, and US/Europe infrastructure growth. Near-term priorities include user growth, Apple Health interoperability, an Android release, Garmin integration, and partnerships with labs, health plans, and specialty providers.
DaVita (NYSE: DVA) named Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective Dec. 11, 2025. Both executives bring more than a decade of experience at DaVita and will lead people, strategy, and innovation efforts—Phillips will oversee DaVita Venture Group and corporate strategy. The appointments emphasize a people-first approach and a focus on technology-driven care transformation.
As of Sept. 30, 2025, DaVita served approximately 293,200 patients at 3,247 outpatient centers worldwide, underscoring the scale behind the leadership shift.